Potentials for the use of diuretic therapy in the clinic of internal diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Diuretics are widely used in the clinic of internal diseases. Loop diuretic torasemide is characterized by high bioavailability and prolonged action, as well as good tolerability without the development of metabolic and electrolyte disturbances. It can be used in the treatment of acute and chronic heart failure, arterial hypertension and chronic kidney disease. The drug not only reduces cardiovascular and sudden mortality, but also reduces the frequency and duration of hospitalizations due to the progression of chronic heart failure, the severity of its clinical manifestations, increases the exercise tolerance, improves the left ventricular diastolic function and the quality of life of patients. All this makes torasemide worthy of wider application when choosing a drug for long-term diuretic therapy in a clinic of internal diseases.

Full Text

Restricted Access

About the authors

Anna G. Yevdokimova

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: aevdokimova@rambler.ru
MD, professor of the Department of hospital therapy №2

Yelena V. Kovalenko

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy №2

Vladimir V. Yevdokimov

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy №2

Olga A. Shuiskaya

A.I. Yevdokimov Moscow state university of medicine and dentistry

cardiologist, Department of hospital therapy №2

References

  1. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е изд. М., 2005. [Metelitsa V.I. Handbook of clinical pharmacology of cardiovascular drugs. 3rd ed. Moscow, 2005 (in Russ.)]
  2. Мухин Н.А., Козловская Л.В., Шилов Е.М. и др. Рациональная фармакотерапия в нефрологии: руководство для практикующих врачей. М.: Литтерра, 2006. 896 c. [Muhin N.A., Kozlovskaja L.V., Shilov Ye.M. et al. Rational pharmacotherapy in nephrology: a guide for practitioners. Moscow: Litterra, 2006. 896 p. (in Russ.)]
  3. Bolke T., Achhammer I. Torasemide: review of its pharmacology and therapeutic use. Drugs Today. 1994;8:1-28.
  4. Barr W.H., Smith H.L., Karnes H.T et al. Torasemide dose proportionality of pharmacokinetics and pharmacodynamics. Prog. Pharmacol. Clinl. Pharmacol. Gustav-Fischer-Verlag: Stuttgart, New York. 1990;8(1):29-37.
  5. Евдокимова А.Г., Коваленко Е.В., Ложкина М.В. и др. Особенности диуретической терапии при хронической сердечной недостаточности. Consilium Medicum. 2016;18(1):32-7 [Evdokimova A.G., Kovalenko Ye.V., Lozhkina M.V. et al. Features of diuretic therapy in chronic heart failure. Consilium Medicum. 2016; 18 (1): 32-37 (in Russ.)]
  6. Brater D.C., Leinfelder J., Anderson S.A. Clinical pharmacology of torasemide, a new loop diuretic. Clin. Pharmacol. Ther. 1987;42:187-92.
  7. Fortuno A., Muniz P., Ravassa S. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34:138-43.
  8. Harada K., Izawa H., Nishizawa T., Murase Y., Kobayashi M., Isobe S., Cheng X.W., Noda A., Nagata K., Yokota M., Murohara T. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J. Cardiovasc. Pharmacol. 2009;53(6):468-73.
  9. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart. 2006;92:1434-40.
  10. Goodfriend T.L., Ball D.L., Oelkers W., Bähr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:97-105.
  11. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 2004;43(11):2028-35.
  12. Lopez B., Gonzalez A., Beaumont J., Querejeta R., Larman M., Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007;50(9): 859-67.
  13. Агеев Ф.Т., Жубрина Е.С., Гиляревский С.Р., Мареев В.Ю., Хосева Е.Н., Голшмид М.В., Деев А.Д., Коткина Т.И., Лукина Ю.В., Малишевский М.В., Масенко В.П., Рогожкина Ю.А., Середенина Е.М., Синицина И.И., Сусликов А.В., Титов В.Н. Сравнительная эффективность и безопасность длительного применения торасемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Сердечная недостаточность. 2013; 14(2):55-62. [Ageev F.T., Zhubrina Ye.S., Gilyarevsky S.R., Mareev V.Yu., Khoseva Ye.N., Goldsmid M.V., Deev A.D., Kotkina T.I., Lukina Yu.V., Malishevsky M.V., Masenko V.P., Rogozhkina Yu.A., Seredinina Ye.M., Sinitsina I.I., Suslikov A.V., Titov V.N. Comparative efficacy and safety of prolonged use of torasemid in patients with compensated heart failure. Influence on markers of myocardial fibrosis. Heart failure. 2013;14(2):55-62. (in Russ.)]
  14. The TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin. Ther. 2011;33(9):1204-13.
  15. Барышникова Г.А., Степанова И.И. Диуретики при артериальной гипертонии: фокус на торасемид. Системные гипертензии. [Baryshnikova G.A., Stepanova I.I. Diuretics in hypertension: focus on torasemid. Systemic hypertension. 2012;9(4):11-16 (in Russ.)]
  16. Castañeda-Hernández G, Caillé G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin. Pharmacokinet. 1994;26(2):135-43.
  17. Miners J.O., Rees D.L., Valente L., Veronese M.E., Birkett D.J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995;272:1076-81.
  18. Spahn H., Knauf H., Mutschler E. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur. J. Clin. Pharmacol. 1990;39:345-8.
  19. Gehr T.W., Rudy D.W., Matzke G.R., Kramer W.G., Sica D.A., Brater D.C. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 1994;56:31-8.
  20. Schwartz S., Brater D.C., Pound D., Green P.K., Kramer W.G., Rudy D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin. Pharmacol. Ther. 1993;54:90-7.
  21. Murray M.D., Haag K.M., Blak P.K., Hall S.D., Brater D.C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 1997;17:98-106.
  22. Veeraveedu P.T., Watanabe K., Ma M., Thandavarayan RA, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2008;75(3):649-598.
  23. Noe L.L., Vreeland M.G., Pezzella S.M., Trotter J.P. A pharmacoenomic аssessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin. Ther. 1999;21(5):854-6.
  24. Xue H., Lu Z., Tang W.L., Pang L.W., Wang G.M., Wong G.W., Wright J.M. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst. Rev. 2015;1:CD008170.
  25. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dom iniczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013;31:1281-357.
  26. Клинические рекомендации «Диагностика и лечение артериальной гипертензии» Российского медицинского общества по артериальной гипертонии, 2013. Кардиологический вестник. 2015;1:10. [Clinical guidelines «Diagnosis and treatment of arterial hypertension» of the Russian medical society on arterial hypertension, 2013. Kardiologichesky vestnik. 2015;1:10 (in Russ.)]
  27. Kent S.T., Shimbo D., Huang L., Diaz K.M., Kilgore M.L., Oparil S., Muntner P. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010. PLoS ONE. 2014;9(8):e105888.
  28. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., Белявская Д.В., Выдрина О.И., Пастернак Е.Ю., Белоусов Д.Ю., Фоминых С.Г. и группа исследователей. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015;1:19-25 [M.V. Leonova, Shteinberg L.L., Belousov Yu.B., Belyavskaya D.V., Vydrina O.I., Pasternak E.Yu., Belousov D.Yu., Fominykh S.G. and group of researchers. Pharmacoepidemiology of hypertension in Russia: analysis of commitment of doctors (according to the study PIFAGOR IV). Systemic hypertension. 2015;1:19-25. (in Russ.)]
  29. Горбунов В.М., Оганов Р.Г. Торасемид - петлевой диуретик с особыми свойствами. Кардиоваскулярная терапия и профилактика. 2006;5(5):70-4. [Gorbunov V.M., Oganov R.G. Torasemid - loop diuretic with special properties. Cardiovascular therapy and prevention. 2006;5(5):70-4 (in Russ.)]
  30. Achhammer I., Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 (Suppl. 3):80-91.
  31. Porcellati C., Verdecchia P., Schillaci G. et al. La torasemide, nuovodiureticodel'ansa, nelltrattamentodell'ipertensionea rteriosa: Studio con trolla to in dopplacecita. Bas. Razion. Terap. 1990;20:407-10.
  32. Baumgart P., Walger P., von Eiff M., Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. Prog. Pharmacol. Clinl. Pharmacol. Stuttgart: Gustav-Fischer-Verlag. 1990;8:169-81.
  33. Spannbrucker N., Achhammer I., Metz P., Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug. Res. 1988;38(1):190-93.
  34. Achhammer I., Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2,5 mg torasemide o. d. or 50 mg triamterene/25 mg hydrochlorothi-azide o.d. Prog. Pharmacol. Clinl. Pharmacol. Stuttgart: Gustav-Fischer-Verlag. 1990;8:211-20.
  35. Stolear I.C., Achhammer I., Georges B. Efficacy of torasemide in the treatment of patients with high-grade renal failure on dialysis. Prog. Pharmacol. Clinl. Pharmacol. Stuttgart: Gustav-Fischer-Verlag. 1990;8:259-67.
  36. Brown N.J. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. 2005;14(3):235-41.
  37. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Рабочая группа членов правления научного общества нефрологов России. Руководитель группы А.В. Смирнов. СПб: Левша, 2012. 54 с. [The national recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. The working group members of the Scientific society of nephrologists of Russia. Saint Petersburg: Levsha, 2012. 54 p. (in Russ.)]
  38. Boesken W.N., Eberwein B., Pieschke L. Efficacy and safety of torasemide (10, 20, 50, 100 and 200 mg/d p.o.) in the reatment of oedema in patients with nephrotic syndrome. Diuretics IV, Proceedings of the 4th.Conference on Diuretics. Elsevier New York, Amsterdam, London, 1993.
  39. Andreucci U.E., Russo D., Memoli B. et al. Efficacy of i.v.torasemide in the treatment of acute and chronic high grade renal failure Prog. Pharmacol. Clinl. Pharmacol. Stuttgart: Gustav-Fischer-Verlag, New York. 1990;8(1).
  40. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., Беленков Ю.Н., Васюк Ю.А., Галявич А.С., Гарганеева А.А., Гиляревский С.Р., Глезер М.Г., Козиолова Н.А., Коц Я.И., Лопатин Ю.М., Мартынов А.И., Моисеев В.С., Ревишвили А.Ш., Ситникова М.Ю., Скибицкий В.В., Соколов Е.И., Сторожаков Г.И., Фомин И.В., Чесникова А.И., Шляхто Е.В. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению хронической сердечной недостаточности (4-й пересмотр). Сердечная недостаточность. 2013;14(7):379-472. [Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteev A.V., Mareev V.Yu., Ovchinnikov A.G., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S., Garganeeva A.A., Gilyarevsky R.S., Glezer M.G., Kosiolova N.A. Kots Ya.I., Lopatin Yu.M., Martynov A.I., Moiseev V.S., Revishvili A.Sh., Sitnikova M.Yu., Skibitsky V.V., Sokolov Ye.I., Storozhakov G.I., Fomin I.V., Chesnikova A.I., Shlyakhto Ye.V. National recommendations on the diagnosis and treatment of chronic heart failure (4th revision). Heart failure. 2013;14(7):379-472 (in Russ.)]
  41. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. РМЖ. 2017; 1 ( 141 ):7-81. [ESC guidelines on the diagnosis and treatment of acute and chronic heart failure 2016. Russian journal of cardiology. 2017;1(141):7-81 (in Russ.)]
  42. Noe L.L., Vreeland M.G., Pezzella S.M., Trotter J.P. A pharmacoenomic аssessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin. Ther. 1999;21(5):854-6.
  43. Cosin J., Diez J., TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002;4:507-13.
  44. Yamato M., Sasaki T., Honda M., Fukuda M., Akutagawa O., Okamoto M., Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat. J. 2003;67(5):384-90.
  45. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диуретическая терапия эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением хронической сердечной недостаточности (ДУЭЛЬ-ХСН). Сердечная недостаточность. 2011;12(3):3-10. [Mareev V.Yu., Vygodin V.A., Belenkov Yu.N. Diuretic therapy is effective doses of oral diuretics of torasemid (diver) and furosemide in the treatment of patients with exacerbation of chronic heart failure (DUEL-CHF). Heart failure. 2011;12(3):3-10. (in Russ.)]
  46. Беркинбаев С.Ф., Джунусбекова Г.А., Исабекова А.Х. Клиническая эффективность петлевого диуретика торасемида в лечении больных хронической сердечной недостаточностью. Результаты казахстанского многоцентрового исследования ПОЭТ. Рациональная фармакотерапия в кардиологии. 2014;10(5):495-9. [Berkinbaev S.F., Dzhunusbekova G.A., Isabekova A.Kh. Clinical efficacy of loop diuretic torasemid in the treatment of patients with chronic heart failure. Results of a multicenter study of the Kazakh POET. Rational pharmacotherapy in cardiology. 2014;10(5):495-9. (in Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies